​

Funding Round

Series C - ImCheck Therapeutics

Series C - ImCheck Therapeutics

Investment Firm

Overview

ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.

Announced Date

Jun 13, 2022

Funding Type

Series C

Highlights

Location

Europe

Social

Investor Lead

Earlybird Venture Capital

Earlybird Venture Capital

Earlybird Venture Capital is a convertible_note and debt and early_stage_venture and late_stage_venture and private_equity and seed firm.

Andera Partners

Andera Partners

Andera Partners is a early_stage_venture and late_stage_venture firm.

Participant Investors

14

Investor Name
Participant InvestorInvus
Participant InvestorEurazeo
Participant InvestorAndera Partners
Participant InvestorWellington Partners
Participant InvestorEarlybird Venture Capital

Round Details and Background

ImCheck Therapeutics raised $99985627 on 2022-06-13 in Series C

ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 04, 2019
Series B - ImCheck Therapeutics
11-53.2M
Sep 15, 2020
Series B - ImCheck Therapeutics
1-7.1M
Jun 13, 2022
Series C - ImCheck Therapeutics
15-100.0M
May 02, 2017
Series A - ImCheck Therapeutics
5-21.9M

Recent Activity

There is no recent news or activity for this profile.